David Chang, Allogene CEO (Credit: Jeff Rumans)

Al­lo­gene Ther­a­peu­tics plans re­struc­tur­ing as it swaps out PhII CAR-T tri­al plans to leapfrog ri­vals

Al­lo­gene Ther­a­peu­tics is switch­ing up clin­i­cal plans for its off-the-shelf CAR-T ther­a­pies. In a bid to leapfrog more es­tab­lished ri­vals, the South San Fran­cis­co biotech will de­pri­or­i­tize two cur­rent Phase II tri­als of its lead can­di­date — its most ad­vanced — and launch a new late-stage study with a much dif­fer­ent de­sign, it an­nounced late Thurs­day.

As a re­sult of the new ap­proach, Al­lo­gene will al­so im­ple­ment a “planned re­struc­tur­ing” this quar­ter to align with the small­er tri­al foot­print and pri­or­i­tized pipeline, the biotech said in a re­lease. While it didn’t spell out spe­cif­ic im­pli­ca­tions, the move is ex­pect­ed to ex­tend its run­way from 2025 in­to 2026.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA